SCHEMBL1040467

SCHEMBL1040467

COc1cc(OC)cc(C(O)CC(CCc2cn(C(c3ccccc3)(c3ccccc3)c3ccccc3)cn2)Cc2ccccc2)c1

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 15/20 0.42
LPAR1 Q92633 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1041621 0.83 SIRT2 (0.46) SIRT2MAPT
SCHEMBL8979144 0.78 SIRT2 (0.42) SIRT2
SCHEMBL8865570 0.72 SIGMAR1 (0.42) SIRT2
SCHEMBL7084465 0.72 SIRT2 (0.44) SIRT2
SCHEMBL1041255 0.69 GPR52 (0.48) SIRT2
SCHEMBL1041256 0.69 GPR52 (0.48) SIRT2
SCHEMBL9069663 0.68 SIRT2 (0.44) SIRT2
SCHEMBL1041247 0.67 SIRT2 (0.38) SIRT2
SCHEMBL18937780 0.66 SIRT2 (0.54) SIRT2
SCHEMBL8865638 0.66 FAAH (0.38) SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9278969-B2 Organic compounds NOVARTIS AG (CH) 2016-03-08 US disclosed
US-20140357621-A1 Organic Compounds NOVARTIS AG (CH) 2014-12-04 US disclosed
EP-2256118-B1 Condensed imidazolo derivatives for the inhibition of aromatase and the treatment of aldosterone related diseases NOVARTIS AG (CH) 2014-10-29 EP disclosed
US-8835646-B2 Organic compounds NOVARTIS AG (CH) 2014-09-16 US disclosed
US-20130287789-A1 Organic Compounds NOVARTIS AG (CH) 2013-10-31 US disclosed
EP-1919916-B1 CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE NOVARTIS AG (CH) 2013-04-03 EP disclosed
US-8314097-B2 Organic compounds NOVARTIS AG (CH) 2012-11-20 US disclosed
US-20120277215-A1 Organic Compounds RECORDATI AG (CH) 2012-11-01 US disclosed
EP-2270011-A1 Condensed imidazolo derivatives for the inhibition of aromatase Novartis AG (CH) 2011-01-05 EP disclosed
EP-2256118-A1 Condensed imidazolo derivatives for the inhibition of aromatase Novartis AG (CH) 2010-12-01 EP disclosed
EP-1919916-A1 CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE Novartis AG (CH) 2008-05-14 EP disclosed
US-20070049616-A1 Organic compounds RECORDATI AG (CH) 2007-03-01 US disclosed
WO-2007024945-A1 CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE NOVARTIS AG (CH) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049616-A1 Organic compounds CYP19A1, CYP17A1, HSD17B11 SIRT2 2715/4885LPAR1 3796/4885MAPT 3983/4885
US-20130287789-A1 Organic Compounds CYP19A1, CYP17A1, HSD17B11 SIRT2 2715/4885LPAR1 3796/4885MAPT 3983/4885
US-20120277215-A1 Organic Compounds CYP19A1, CYP17A1, HSD17B11 SIRT2 2715/4885LPAR1 3796/4885MAPT 3983/4885
US-20140357621-A1 Organic Compounds CYP19A1, CYP17A1, HSD17B11 SIRT2 2715/4885LPAR1 3796/4885MAPT 3983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.